Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Beginner's Mind

Beginner's Mind artwork

EP 153 - Christopher Uhde: The Biotech IPO Boom is Over. Now What?

Feb 21, 20252 hr 4 minAudio
ShareXLinkedInFacebookWhatsAppEmail

In 2021, biotech IPOs were soaring. Valuations hit record highs. Investors were throwing money at anything that moved. Then… the market crashed. Funding dried up. Growth stalled. Biotech founders and investors were left scrambling. So what really happened? And more importantly - how do you navigate what’s next? 📌 In this episode, Christopher Uhde - Senior Pharma & Biotech Equity Analyst at SEB - breaks down the brutal realities of biotech IPOs, investor sentiment, and the high-stakes game of survival in a post-boom world. 🎧 Watch now to learn: 1️⃣ Why valuations aren’t about science - but about demand. 2️⃣ The biggest mistake biotech founders make after going public. 3️⃣ How to raise capital before you actually need it. 4️⃣ The European biotech advantage - and how to leverage it. 5️⃣ How to attract the right investors and avoid the wrong ones. 👤 About Christopher Uhde: Christopher Uhde is a Senior Pharma & Biotech Equity Analyst at SEB, one of Europe’s leading financial institutions. With a PhD in neurodevelopmental systems biology and postdoctoral research in drug discovery, he’s spent years studying the biotech market - from billion-dollar giants to early-stage startups - analyzing their success, failures, and what separates winners from the rest. 💡 Quotes to Challenge Your Thinking: 📌 (00:16:29) "Valuation isn’t about science; it’s about demand and the right investors." 📌 (00:49:17) "The power of the right team in biotech can’t be overstated." 📌 (01:13:08) "European startups struggle not from lack of innovation, but from a lack of ownership mindset." 📌 (01:38:39) "The long-term equity story isn’t just about share price - it’s about trust and vision." 📌 (01:50:44) "Biotech isn’t just about breakthrough science - it’s about strategy, trust, and long-term vision." ⏰ Timestamps: (00:09:48) IPO Market Realities and Investor Sentiment (00:17:59) Why European biotech should think beyond US listings (00:25:15) The hidden challenges of taking a company public (00:28:45) Preparing for IPO Compliance (00:37:11) Public company leadership demands strategic communication (00:49:17) The power of the right team in biotech (00:52:48) Planning for success in biotech acquisitions (01:13:08) Incentivizing Innovation in Europe (01:23:33) Nordic IPO culture shaping biotech success (01:36:16) Realistic Communication in Biotech (01:50:44) Europe’s Biotech Global Edge 🔔 Help Us Grow If this episode gave you insight, inspiration, or a new perspective - here’s how you can help: 📢 Hit SUBSCRIBE, like, and leave a comment. It’s a small action, but it makes a huge difference. Every engagement helps us bring in more top-tier guests, deeper insights, and the conversations that keep you ahead. Right now, we’re in the global top 10% - let’s push for the top 1% together. 🎧 Watch now and make sure your biotech strategy is built to last. 🚀 Send us Fan Mail Support the show Join the Podcast Newsletter: Link Your Next Move: Link

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Spark 20: Alex Dang | Everyone Agrees? Think Again. How Venture Capitalists Decide

    Nov 1, 202629 minAudio

    Invest in the wrong startup and you lose one times your money. Miss the next Google and you lose ten thousand times. Most boards are built to avoid the first mistake. Venture capitalists play by different rules. They...

    Credit the people on this episode

  2. EP 185: Ivy Nguyen | IQ, EQ and the Execution Quotient Investors Fund

    Oct 18, 20261 hr 4 minAudio

    The trait a Silicon Valley AI investor rewards most in a management team has a name almost nobody uses: XQ. IQ brings the idea and EQ reads the people across the table. The execution quotient shows in something as small...

    Credit the people on this episode

  3. EP 184: Ivy Nguyen | 10,000 AI Pitches and the One Test That Matters

    Oct 15, 202659 minAudio

    In 2017 another investor told Ivy Nguyen that artificial intelligence was too small a niche to dedicate a fund to. More than ten thousand AI pitches later, every pitch deck says AI. Single funding rounds have grown...

    Credit the people on this episode

  4. EP 183: Marie Schroeder | Send the Rough Deck, Not the Perfect One

    Sep 27, 20262 hr 5 minAudio

    A seed investor at Novo Holdings would rather read your rough idea than your finished pitch deck. Most founders spend a year building the deck, forming the team and waiting until the story holds together. By the time it...

    Credit the people on this episode

  5. #182 - How to Lead When You Don't Know Where You Are Going: 4 Lessons from Ben Horowitz (Part 2 of 2)

    Sep 8, 202657 minAudio

    What does it mean when the most respected adviser in Silicon Valley tells you that you are the best chief executive he works with, while your company is heading straight into a wall? Bill Campbell said exactly that to...

    Credit the people on this episode